Abstract 140P
Background
Preoperative and postoperative C-reactive protein (CRP) levels are related to the prognosis for cancer patients. This study aimed to explore the predictive value of combining the two in gastric cancer (GC) patients.
Methods
Patients in a clinical trial (NCT02327481) from January 2015 to April 2016 were analyzed. Receiver operating characteristic curves (ROCs) were generated. By calculating the areas under the curve (AUC) and the C-index, the discriminative ability of CRP during different periods were compared, including preoperative (pre-CRP), postoperative days 1, 3, and 5 (post-CRPs) and postoperative maximum CRP (post-CRPmax).
Results
Ultimately, 401 patients were included in this study. The median follow-up time was 42 months (range 3-51 months). For postoperative recurrence, the AUC and C-index of pre-CRP were 0.692 and 0.678, respectively, higher than those for post-CRPs, all p<0.05. Among post-CRPs, post-CRPmax had the highest AUC (0.591) and C-index (0.585). The optimal cut-off values for pre-CRP and post-CRPmax were 3.1mg/L and 77.1mg/L, respectively. Multivariate analysis showed both pre-CRP≥3.1mg/L (high-pre-CRP) and post-CRPmax≥77.1mg/L (high-post-CRPmax) were independent factors for recurrence-free survival (RFS). The model consisting of the pre-CRP, post-CRPmax and TNM had higher predictive ability and clinical utility. Adjuvant chemotherapy (ACT) benefit analysis for stage II/III GC showed patients with pre-CRP<3.1mg/L did not benefit from chemotherapy (RFS:90.0% nonchemotherapy group vs 80.7% chemotherapy group, p=0.557). In the high-pre-CRP group, only patients with high-post-CRPmax but not post-CRPmax<77.1mg/L benefited from chemotherapy (RFS:33.2% nonchemotherapy group vs 49.9% chemotherapy group, p=0.037). Similar findings were observed for overall survival.
Conclusions
Both pre-CRP and post-CRPmax, inexpensively and easily obtained, are independent predictors of recurrence for GC. ACT significantly prolonged the RFS for stage II/III GC with high-pre-CRP and high-post-CRPmax after R0 resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session